Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?Zacks Investment Research • 07/25/25
U.S. Keytruda Market Research Report 2025 | Merck's Keytruda Faces Challenges as Patent Expiry Approaches in 2028 - Forecast to 2033GlobeNewsWire • 07/25/25
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?Zacks Investment Research • 07/23/25
Rapid Micro Biosystems: Benefiting From Partnership With Merck; Initiating With 'Buy'Seeking Alpha • 07/22/25
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 07/19/25
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 07/18/25
Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking SolutionsGlobeNewsWire • 07/18/25
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Zacks Investment Research • 07/17/25
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its BusinessThe Motley Fool • 07/17/25
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone paymentGlobeNewsWire • 07/16/25
Merck Starts Phase III Studies on Once-Monthly Pill for HIV PreventionZacks Investment Research • 07/15/25
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?Zacks Investment Research • 07/14/25
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention PillBusiness Wire • 07/14/25
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNABusiness Wire • 07/13/25